Weight loss and recorded adverse-event patterns differed between agents.
The research question
What outcomes accompany sustained initiation-dose prescribing?
Overview
The study examined sustained prescribing at initiation doses in routine care.
Study design & methods
Federated EHR criteria identified 814 patients repeatedly prescribed semaglutide 0.25 mg and 1,016 prescribed tirzepatide 2.5 mg over at least six months. Matched analyses used clinical-note curation.
Principal findings
Twelve-month weight changes were −5.5% with tirzepatide versus −2.2% with semaglutide. Tirzepatide had higher recorded constipation and acute kidney injury rates over twenty-four months.
Limitations & interpretation
Observational prescription patterns do not confirm ingestion, intentional microdosing or causal treatment effects. Selection, access, tolerability and residual confounding may influence comparisons; prospective validation is needed.
Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.